Buried within the FDA’s briefing document for the Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting on December 10, 2020, for the Pfizer-BioNTech COVID-19 Vaccine — there is alarming data and a concerning issue that should be addressed. Firstly, it’s worth pointing out that Pfizer used a ‘central laboratory’ (see page 13 of the document) of […]
Vaccines
Documents Reveal Lipid Nanoparticles in Pfizer Vaccine Travel From Injection Site, J&J Virus Particles Present Months After Jab
Judicial Watch announced Tuesday it received 466 pages of records from the Department of Health and Human Services (HHS) containing biodistribution studies and related data for COVID-19 vaccines that show lipid nanoparticles (LNPs) contained in Pfizer’s COVID-19 vaccine travel outside the injection site and settle primarily in the liver, adrenal glands, spleen and ovaries of test […]
Pfizer’s ‘Fully Approved’ Comirnaty Vaccine is Still Not Available in the U.S.
On August 23, 2021, the US Food and Drug Administration (FDA) approved Pfizer’s biological licensing application (BLA) for its COVID-19 vaccine named COMIRNATY for people aged 16yrs and older. At the time, vaccine hesitancy was persistent and the acting FDA Commissioner Janet Woodcock said that granting full approval to the vaccine might “instill additional confidence” in people to get […]
Moderna Asks FDA to Authorize COVID Vaccine for Infants and Kids Under 6 After Changing Efficacy Number
Moderna announced Thursday it has submitted a request for Emergency Use Authorization (EUA) of its COVID vaccine mRNA-1273 for children 6 months to under 2 years and 2 years to under 6 years of age to the U.S. Food and Drug Administration (FDA). “We believe mRNA-1273 will be able to safely protect these children against […]
Pfizer Requests Emergency Use Authorization for COVID Vaccine Booster in Children 5 to 11
Pfizer and BioNTech on Tuesday asked the U.S. Food and Drug Administration (FDA) to authorize the first COVID booster shot for children aged 5 to 11. In a press release, Pfizer cited data from its Phase 2/3 trial and claimed a third dose produced a “strong immune response” in the younger age group when administered […]